Jeffrey M Johnston

Summary

Publications

  1. pmc A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation
    Satish Rao
    Section of Gastroenterology Hepatology, Georgia Health Sciences University, Augusta, Georgia, USA
    Am J Gastroenterol 107:1714-24; quiz p.1725. 2012
  2. doi request reprint A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation
    Jeffrey M Johnston
    Ironwood Pharmaceuticals, Inc, Cambridge, MA, USA
    Curr Med Res Opin 29:149-60. 2013
  3. doi request reprint Pilot study on the effect of linaclotide in patients with chronic constipation
    Jeffrey M Johnston
    Ironwood Pharmaceuticals, Inc, 320 Bent Street, Cambridge, MA, USA
    Am J Gastroenterol 104:125-32. 2009
  4. doi request reprint Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation
    Jeffrey M Johnston
    Ironwood Pharmaceuticals, Inc, Cambridge, Massachusetts, USA
    Gastroenterology 139:1877-1886.e2. 2010
  5. ncbi request reprint Clarification of trial end points presented in a recent review of linaclotide
    Jeffrey M Johnston
    Ironwood Pharmaceuticals, Inc, 301 Binney Street, Cambridge, MA 02142, USA
    Expert Rev Gastroenterol Hepatol 6:13-4. 2012
  6. ncbi request reprint Two randomized trials of linaclotide for chronic constipation
    Anthony J Lembo
    Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA, USA
    N Engl J Med 365:527-36. 2011
  7. doi request reprint Efficacy of linaclotide for patients with chronic constipation
    Anthony J Lembo
    Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 138:886-95.e1. 2010
  8. doi request reprint Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation
    Satish S C Rao
    Section of Gastroenterology and Hepatology, Georgia Regents University, Augusta, Georgia
    Clin Gastroenterol Hepatol 12:616-23. 2014

Collaborators

  • Anthony J Lembo
  • Satish S C Rao
  • Caroline B Kurtz
  • Mark G Currie
  • Steven J Shiff
  • Bernard J Lavins
  • James E MacDougall
  • Satish Rao
  • Eamonn M M Quigley
  • Paul Eng
  • Susan M Fox
  • Xinwei D Jia
  • Kelvin Shi
  • Harvey A Schneier
  • James Z Shao

Detail Information

Publications8

  1. pmc A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation
    Satish Rao
    Section of Gastroenterology Hepatology, Georgia Health Sciences University, Augusta, Georgia, USA
    Am J Gastroenterol 107:1714-24; quiz p.1725. 2012
    ..Linaclotide is a minimally absorbed guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C)...
  2. doi request reprint A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation
    Jeffrey M Johnston
    Ironwood Pharmaceuticals, Inc, Cambridge, MA, USA
    Curr Med Res Opin 29:149-60. 2013
    ....
  3. doi request reprint Pilot study on the effect of linaclotide in patients with chronic constipation
    Jeffrey M Johnston
    Ironwood Pharmaceuticals, Inc, 320 Bent Street, Cambridge, MA, USA
    Am J Gastroenterol 104:125-32. 2009
    ..In Phase 1 studies in healthy human volunteers, linaclotide was well-tolerated, increased bowel movement frequency, and loosened stool consistency...
  4. doi request reprint Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation
    Jeffrey M Johnston
    Ironwood Pharmaceuticals, Inc, Cambridge, Massachusetts, USA
    Gastroenterology 139:1877-1886.e2. 2010
    ..We assessed the efficacy and safety of linaclotide at a daily dose range of 75-600 μg in IBS-C...
  5. ncbi request reprint Clarification of trial end points presented in a recent review of linaclotide
    Jeffrey M Johnston
    Ironwood Pharmaceuticals, Inc, 301 Binney Street, Cambridge, MA 02142, USA
    Expert Rev Gastroenterol Hepatol 6:13-4. 2012
    ..Response to: Roque MV, Camilleri M. Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation. Expert Rev. Gastroenterol. Hepatol. 5(3), 301-310 (2011)...
  6. ncbi request reprint Two randomized trials of linaclotide for chronic constipation
    Anthony J Lembo
    Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA, USA
    N Engl J Med 365:527-36. 2011
    ..Linaclotide is a minimally absorbed peptide agonist of the guanylate cyclase C receptor. In two trials, we aimed to determine the efficacy and safety of linaclotide in patients with chronic constipation...
  7. doi request reprint Efficacy of linaclotide for patients with chronic constipation
    Anthony J Lembo
    Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 138:886-95.e1. 2010
    ..We assessed the safety and efficacy of a range of linaclotide doses in patients with chronic constipation...
  8. doi request reprint Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation
    Satish S C Rao
    Section of Gastroenterology and Hepatology, Georgia Regents University, Augusta, Georgia
    Clin Gastroenterol Hepatol 12:616-23. 2014
    ..We examined the prevalence of severe abdominal symptoms in patients with IBS-C and assessed the effects of linaclotide on abdominal symptoms, global measures, and quality of life (QOL)...